The majority of patients with diffuse large B-cell lymphoma (DLBCL) can be treated successfully with a combination of chemotherapy and the monoclonal anti-CD20 antibody rituximab. This evidence concerns the gene MS4A1 and diffuse large B-cell lymphoma.